Melina Rodriguez: FDA Approves Imaavy as First Treatment for Warm AIHA
Melina Rodriguez, Founder of Health Evidence Digest, Senior Medical Editor at Precision AQ, shared a post on LinkedIn:
“Imaavy (Nipocalimab) Receives FDA Approval as the First-Ever Treatment Proven Safe and Effective Specifically for Warm Autoimmune Hemolytic Anemia, Ending Decades of Off-Label Management With Non-Specific Immunosuppression.
On August 24, 2026, the FDA approved Imaavy (nipocalimab-aahu, Johnson and Johnson) as the first-ever treatment proven safe and effective for warm autoimmune hemolytic anemia.
Phase 2/3 ENERGY showed approximately 3x more patients achieved durable hemoglobin response versus placebo; mean hemoglobin improvement began at week 1.
Here is how FcRn blockade selectively reduces pathogenic IgG without broad immunosuppression and what the complete trial data shows….”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 01:43Oliver Weingärtner: Deprescribing of Lipid Lowering Drug after MI is Associated with Cardiovascular Events
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge